Skip to main content

Table 2 Patient characteristics in the case-control series: patients in the discovery cohort GWDb

From: Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study

 

V cases

V controls

BV cases

BV controls

B cases

B controls

Case series

Number of patients

105

82

106

86

98

90

χ 2

p

Age at hist. diag.

Median (years)

55.4

52.0

52.5

50.3

55.9

48.8

  

Grade

1

3 (3%)

12 (15%)

3 (3%)

13 (15%)

8 (8%)

7 (8%)

  
 

2

27 (26%)

32 (39%)

44 (42%)

47 (55%)

44 (45%)

42 (47%)

  
 

3

68 (65%)

34 (41%)

55 (52%)

19 (22%)

38 (39%)

37 (41%)

  
 

Unknown

7 (7%)

4 (5%)

4 (4%)

7 (8%)

8 (8%)

4 (4%)

18.2

0.01

ER IHC status

Positive

57 (54%)

52 (63%)

69 (65%)

62 (72%)

77 (79%)

65 (72%)

  
 

Negative

48 (46%)

30 (37%)

37 (35%)

24 (28%)

21 (21%)

25 (28%)

13.3

0.001

PR status

Positive

39 (37%)

40 (49%)

53 (50%)

56 (65%)

59 (60%)

51 (57%)

  
 

Negative

66 (63%)

42 (51%)

53 (50%)

30 (35%)

39 (40%)

39 (43%)

10.9

0.004

HER2 status

Positive

31 (30%)

13 (16%)

22 (21%)

13 (15%)

15 (15%)

11 (12%)

  
 

Negative

44 (42%)

38 (46%)

51 (48%)

41 (48%)

45 (46%)

42 (47%)

  
 

Unknown

30 (29%)

31 (38%)

33 (31%)

32 (37%)

38 (39%)

37 (41%)

7.0

0.1

Tumour size

<= 2 cm

41 (39%)

39 (48%)

39 (37%)

44 (51%)

38 (39%)

47 (52%)

  
 

>2 cm

64 (61%)

42 (51%)

65 (61%)

38 (44%)

60 (61%)

41 (46%)

0.1

1.0

 

Unknown

-- --

1 (1%)

2 (2%)

4 (5%)

-- --

2 (2%)

  

Lymph nodes positive

0

15 (14%)

33 (40%)

21 (20%)

32 (37%)

24 (24%)

39 (43%)

  
 

1–3

34 (32%)

29 (35%)

31 (29%)

28 (33%)

30 (31%)

30 (33%)

  
 

4+

37 (35%)

10 (12%)

40 (38%)

11 (13%)

26 (27%)

10 (11%)

  
 

Unknown

19 (18%)

10 (12%)

14 (13%)

15 (17%)

18 (18%)

11 (12%)

6.1

0.4

Invasive subtype

NOS/no special type

96 (91%)

70 (85%)

85 (82%)

73 (85%)

82 (84%)

81 (90%)

  
 

Ductal - mucinous

-- --

2 (2%)

1 (1%)

-- --

1 (1%)

1 (1%)

  
 

Ductal - tubular

-- --

-- --

1 (1%)

3 (3%)

2 (2%)

1 (1%)

  
 

Ductal - other

1 (1%)

1 (1%)

1 (1%)

-- --

-- --

3 (3%)

  
 

Lobular - classical

5 (5%)

5 (6%)

7 (7%)

9 (10%)

12 (12%)

2 (2%)

  
 

Lobular - pleomorphic

1 (1%)

1 (1%)

6 (6%)

-- --

-- --

1 (1%)

  
 

Lobular - other

-- --

2 (2%)

2 (2%)

1 (1%)

1 (1%)

-- --

  
 

Other

2 (2%)

1 (1%)

1 (1%)

-- --

-- --

1 (1%)

1.7

0.4 †

Surgery type (any time)

Breast conserving

30 (29%)

34 (41%)

35 (33%)

43 (50%)

31 (32%)

39 (43%)

  
 

Breast conserving + mastectomy

17 (16%)

11 (13%)

19 (18%)

7 (8%)

15 (15%)

13 (14%)

  
 

Mastectomy

47 (45%)

33 (40%)

41 (39%)

30 (35%)

43 (44%)

35 (39%)

  
 

Unknown

11 (10%)

4 (5%)

11 (10%)

6 (7%)

9 (9%)

3 (3%)

1.2

1.0

Radiotherapy (adj/neo)

Yes

79 (75%)

52 (63%)

84 (79%)

55 (64%)

82 (84%)

59 (66%)

  
 

No

26 (25%)

30 (37%)

22 (21%)

31 (36%)

16 (16%)

31 (34%)

2.2

0.3

Hormone treatment (adj/neo)

Yes

84 (80%)

38 (46%)

97 (92%)

57 (66%)

92 (94%)

51 (57%)

  
 

No

21 (20%)

44 (54%)

9 (8%)

29 (34%)

6 (6%)

39 (43%)

11.0

0.004

Chemotherapy

Neo-adj only

-- --

2 (2%)

2 (2%)

1 (1%)

5 (5%)

3 (3%)

  
 

Neo-adj and adj

4 (4%)

-- --

4 (4%)

1 (1%)

1 (1%)

-- --

  
 

Adj only

65 (62%)

33 (40%)

67 (63%)

24 (28%)

43 (44%)

28 (31%)

  
 

No

36 (34%)

47 (57%)

33 (31%)

60 (70%)

49 (50%)

59 (66%)

8.7

0.01 ‡

Metastatic events in control series

No mets, 64 (78%)

V = 8, BV = 8, B = 2

No mets, 66 (77%)

V = 10, BV = 5, B = 5

No mets, 69 (77%)

V = 4, BV = 10, B = 7

 
  1. †ductal versus lobular, ‡any versus no chemotherapy. Abbreviations as for Table 1